LY164929: a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Neuropeptides

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0143-4179(88)90022-4PMID 2835701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824.

  1987cited by this paper
• Biphasic competition between opiates and enkephalins: does it indicate the existence of a common high affinity ("mu-1") binding site?

  1987cited by this paper
• Morphine tolerance increases mu-noncompetitive delta binding sites.

  1986cited by this paper
• Morphine tolerance increases -noncompetative d binding sites?

  1986cited by this paper
• Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: evidence for delta----mu binding site interactions in vitro.

  1985cited by this paper
• A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site.

  1985cited by this paper
• Probes for narcotic receptor mediated phenomena. XI: Synthesis of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinans (foxy and cyclofoxy) as models of opioid ligands suitable for positron emission transaxial tomography

  1985cited by this paper
• Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies.

  1985cited by this paper
• Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding site.

  1985cited by this paper
• Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies.

  1985cited by this paper
• Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: a highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding.

  1984cited by this paper
• Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: evidence for a two-site allosteric model.

  1984cited by this paper
• Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: evidence for a two-site allosteric model.

  1984cited by this paper
• Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors.

  1983cited by this paper
• Evaluation of the interactions of mu and delta selective ligands with [3H]D-Ala2-D-Leu5-enkephalin binding to mouse brain membranes.

  1983cited by this paper
• High and low affinity opioid binding sites: relationship to mu and delta sites.

  1982cited by this paper
• Enhancement of delta- but not mu-opiate agonist binding by calcium.

  1982cited by this paper
• Morphiceptin (NH4-tyr-pro-phe-pro-COHN2): a potent and specific agonist for morphine (mu) receptors.

  1981cited by this paper
• Analogues of β-LPH61–64 posessing selective agonist activity at μ-opiate receptors

  1981cited by this paper
• Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors.

  1981cited by this paper
• Statistical characterization of the random errors in the radioimmunoassay dose--response variable.

  1976cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].

  2004cites this paper
• Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.

  2003cites this paper
• Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans.

  2002cites this paper
• delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.

  1999cites this paper
• Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic δ opioid receptor ligands

  1999cites this paper
• Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.

  1999cites this paper
• Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.

  1999cites this paper
• Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.

  1998cites this paper
• Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.

  1997cites this paper
• Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid re

  1997cites this paper
• Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.

  1996cites this paper
• Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands.

  1995cites this paper
• (E)-8-benzylidene derivatives of 2-methyl-5-(3-hydroxyphenyl)morphans: highly selective ligands for the sigma 2 receptor subtype.

  1995cites this paper
• Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)- 3-methyl-4-piperidyl]-N-phenylpropanamides: synthesis, X-ray analysis, and biological activities.

  1995cites this paper
• Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors.

  1994cites this paper
• Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-famide (NPFF) and A-18-famide, for opioid μ, δ, κ1, κ2a, or κ2b receptors

  1994cites this paper
• A marked change of receptor affinity of the 2-methyl-5-(3-hydroxyphenyl)morphans upon attachment of an (E)-8-benzylidene moiety: synthesis and evaluation of a new class of sigma receptor ligands.

  1994cites this paper
• Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the κ2B (enkephalin-sensitive) binding site

  1993cites this paper
• Allosteric Coupling Among Opioid Receptors: Evidence for an Opioid Receptor Complex

  1993cites this paper
• Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the kappa 2B (enkephalin-sensitive) binding site.

  1993cites this paper
• Differential binding of opioid peptides and other drugs to two subtypes of opioid binding sites in mouse brain: Further evidence for δ receptor heterogeneity

  1993cites this paper
• Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: further evidence for delta receptor heterogeneity.

  1993cites this paper
• Interaction of opioid peptides and other drugs with multiple δncx binding sites in rat brain: Further evidence for heterogeneity

  1992cites this paper
• Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that μ ligands are noncompetitive inhibitors of the δcx opioid peptide binding site

  1992cites this paper
• A study of the effect of the irreversible delta receptor antagonist [D-Ala2,Leu5,Cys6]-enkephalin on delta cx and delta ncx opioid binding sites in vitro and in vivo.

  1992cites this paper
• Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-

  1992cites this paper
• A study of the effect of the irreversible delta receptor antagonist [d-Ala2,Leu5,Cys6]Enkephalin on δcx and δncx opioid binding sites in vitro and in vivo

  1992cites this paper
• Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that mu ligands are noncompetitive inhibitors of the delta cx opioid peptide binding site.

  1992cites this paper
• Interaction of opioid peptides and other drugs with multiple delta ncx binding sites in rat brain: further evidence for heterogeneity.

  1992cites this paper
• RTI-4614-4: an analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sites.

  1991cites this paper
• Probing the opioid receptor complex with (+)-trans-superfit. I. Evidence that [D-Pen2,D-Pen5]enkephalin interacts with high affinity at the delta cx binding site.

  1991cites this paper
• Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.

  1991cites this paper
• Probing the opioid receptor complex with (+)-trans-superfit. I. Evidence that [D-Pen2,D-Pen5]enkephalin interacts with high affinity at the δcx binding site

  1991cites this paper
• (+)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: evidence for pseudoallosteric modulation.

  1991cites this paper
• Preliminary ligand binding data for subtypes of the delta opioid receptor in rat brain membranes.

  1991cites this paper
• Interaction of β‐funaltrexamine with [3H]cycloFOXY binding in rat brain: Further evidence that β‐FNA alkylates the opioid receptor complex

  1991cites this paper
• Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet amide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands.

  1990cites this paper
• The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: evidence for a novel mechanism of action.

  1990cites this paper
• A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivo.

  1989cites this paper
• Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sites.

  1989cites this paper
• Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.

  1989cites this paper
• Probes for narcotic receptor mediated phenomena. 15. (3S,4S)-(+)-trans-3-methylfentanyl isothiocyanate, a potent site-directed acylating agent for the delta opioid receptors in vitro.

  1989cites this paper
• Pharmacological activities of optically pure enantiomers of the κ opioid agonist, U50,488, and its cis diastereomer: evidence for three κ receptor subtypes

  1989cites this paper
• Selective and enantiospecific acylation of kappa opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexy l] benzeneacetamide. Demonstration of kappa receptor heterogeneity.

  1989cites this paper
• A brief study of the selectivity of norbinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitro.

  1988cites this paper
• beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.

  1988cites this paper